Capricor Therapeutics Statistics
Capricor Therapeutics (4LN2) Stock Statistics & Valuation Metrics
Total Valuation
Capricor Therapeutics has a market cap or net worth of EUR 464.73M. The enterprise value is EUR 445.13M.
- Market Cap
- EUR 464.73M
- Enterprise Value
- EUR 445.13M
Share Statistics
Capricor Therapeutics has 58,138,990 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 58,138,990
- Owned by Insiders
- 0.93%
- Owned by Institutions
- 20.47%
Financial Efficiency
Capricor Therapeutics’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -33.40%.
- Return on Equity (ROE)
- -0.34
- Return on Assets (ROA)
- -0.30
- Return on Invested Capital (ROIC)
- -33.40%
- Return on Capital Employed (ROCE)
- -0.34
- Revenue Per Employee
- 0
- Profits Per Employee
- -454.74K
- Employee Count
- 231
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Capricor Therapeutics is -4.25. Capricor Therapeutics’s PEG ratio is 0.12.
- PE Ratio
- -4.25
- PS Ratio
- 0.00
- PB Ratio
- 3.11
- Price to FCF
- -5.01
- Price to Operating Cash Flow
- -6.27
- PEG Ratio
- 0.12
Income Statement
In the last 12 months, Capricor Therapeutics had revenue of 0 and earned -105.04M in profits. Earnings per share was -2.26.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -108.14M
- Pretax Income
- -105.04M
- Net Income
- -105.04M
- EBITDA
- -100.11M
- Earnings Per Share (EPS)
- -2.26
Cash Flow
In the last 12 months, operating cash flow was -104.00M and capital expenditures -25.78M, giving a free cash flow of -129.78M billion.
- Operating Cash Flow
- -104.00M
- Free Cash Flow
- -129.78M
- Free Cash Flow per Share
- -2.23
Dividends & Yields
Capricor Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -20.51%
- Earnings Yield
- -23.23%
Stock Price Statistics
- Beta
- 1.19
- 52-Week Price Change
- 81.64%
- 50-Day Moving Average
- 7.04
- 200-Day Moving Average
- 16.83
- Relative Strength Index (RSI)
- 73.16
- Average Volume (3m)
- 2,963
Important Dates
Capricor Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Capricor Therapeutics as a current ratio of 9.01, with Debt / Equity ratio of 5.87%
- Current Ratio
- 9.01
- Quick Ratio
- 9.01
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.70
- Interest Coverage Ratio
- -35.51
Taxes
In the past 12 months, Capricor Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Capricor Therapeutics EV to EBITDA ratio is 0.59, with an EV/FCF ratio of -5.24.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.59
- EV to Free Cash Flow
- -5.24
- EV to Operating Cash Flow
- -6.54
Balance Sheet
Capricor Therapeutics has EUR 237.93M in cash and marketable securities with EUR 91.05M in debt, giving a net cash position of EUR 146.89M billion.
- Cash & Marketable Securities
- EUR 237.93M
- Total Debt
- EUR 91.05M
- Net Cash
- EUR 146.89M
- Net Cash Per Share
- EUR 2.53
- Tangible Book Value Per Share
- EUR 4.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Capricor Therapeutics is EUR 24.96, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 24.96
- Price Target Upside
- 179.04% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- -40.84%
Scores
- Smart Score
- 6
- AI Score
- ―
